Doxycycline, unlike older tetracyclines, retains activity against many resistant strains. The resistance mechanism that doxycycline partially overcomes compared to tetracycline is:

• A Ribosomal protection proteins (RPPs) such as TetM/TetO that displace tetracycline from the ribosome — doxycycline's higher affinity for the ribosome partially competes with RPP displacement
• B Tet(A/B/C) efflux pumps — doxycycline is a poorer substrate for these MFS transporters due to higher lipophilicity ✓
• C Enzymatic inactivation by tetracycline oxidases (TetX) — doxycycline is more resistant to oxidation than tetracycline
• D Outer membrane porin mutation in gram-negatives — doxycycline enters via passive diffusion and is less dependent on OmpF/OmpC porins

Explanation

The primary tetracycline resistance mechanism in gram-negatives involves plasmid-encoded efflux pumps (Tet(A), Tet(B), Tet(C) — MFS family). Tetracycline is efficiently transported by these pumps out of the cell. Doxycycline's increased lipophilicity (and minocycline's even higher lipophilicity) makes them poorer substrates for these efflux pumps, improving intracellular accumulation in resistant strains. Ribosomal protection proteins (TetM/TetO) confer broad resistance against all tetracyclines including doxycycline. TetX enzymatic inactivation is the emerging resistance mechanism but not classically distinguished between doxycycline and tetracycline. This is why tigecycline (a glycylcycline) was developed: its 9-glycylamide modification overcomes both efflux and ribosomal protection.

Reference: KD Tripathi, Essentials of Medical Pharmacology, 8th ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.